HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Zydus Lifesciences gets NoC for generic Mesalamine suppositories 1000 mg
Oct-27-2025

Zydus Lifesciences has received Notice of Compliance (NoC) from Health Canada for generic Mesalamine suppositories 1000 mg. Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis.

ZDS - Mesalamine suppositories will be manufactured at Zydus Lifesciences Changodar, Ahmedabad in Gujarat, India. Mesalamine suppositories had annual sales of 4.86 million CAD (Canadian Dollars) in Canada (IQVIA MAT June 2025). 

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

  RELATED NEWS >>